MedPath

The Effects of a 12 Week Home-based Exercise Intervention on Physical Performance in Patients With Cancers of the Gastrointestinal Tract With Pre- Cachexia or Cachexia

Not Applicable
Completed
Conditions
Cachexia
Weight Loss
Gastrointestinal Cancer
Interventions
Other: EXCAP©®
Registration Number
NCT04802486
Lead Sponsor
University of Rochester
Brief Summary

The main purpose of this research study is to determine if exercise improve or worsen cachexia.

Detailed Description

In this study the investigator would like to better understand how cachexia may improve or worsen, and how exercise may impact this process. The investigator would like to see whether a progressive resistance exercise program (EXCAP©®, Exercise for Cancer Patients) can improve symptoms in patients with gastrointestinal cancers with weight loss and cachexia. The investigator would also like to find out if this exercise intervention improves physical performance, day-to-day function, quality of life, and how exercise may affect different markers in the blood over time.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
25
Inclusion Criteria
  • Have a primary diagnosis of colorectal, esophageal, gastric, pancreatic or biliary tract cancer and plans to initiate systemic chemotherapy within the next 4 weeks after enrollment.
  • Have been diagnosed as having an advanced unresectable cancer with no plans for surgical intervention during the active study period (12 weeks).
  • Have an ECOG performance score of 0 or 1.
  • Have a life expectancy of >3 months as determined by their primary oncologist.
  • Have experienced at least 2% weight loss of the patient's reported previous body weight over the 6 months prior to enrollment. Patients who have 2 - 4.9% weight loss should also have one of the following metabolic changes: a hemoglobin level <13, an albumin level <3.5, and/or impaired glucose tolerance within the past year such as a new diagnosis of diabetes, an A1C level >5.7, a random glucose level >200 or a fasting glucose level >100.
  • Have permission from primary oncologist to engage in low to moderate intensity exercise regimen.
  • Be able to read English (since the assessment materials are in printed format).
  • Be able to give written informed consent.
Exclusion Criteria
  • Have any of the following limitations: unable to walk the 4 meters of the SPPB test, wheel-chair bound, unable to perform low-to-moderate intensity exercise regimen (patients unable to perform 6 minute walk or stair climb test will be allowed to participate, but will be held out of these measurements).
  • Have had major surgery (excluding diagnostic procedures like laparoscopy, EGD/EUS, esophageal stent placement) in the past 4 weeks.
  • Be experiencing dysphagia that requires enteral or parenteral feeding for nutrition.
  • Be enrolled on hospice at time of consent.
  • Be engaged in an active exercise routine by being identified as in the Active or Maintenance Stage of exercise behavior as assessed by the 1-item Exercise Stages of Change Short Form (40).

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Arm 1: Exercise Intervention and Standard CareEXCAP©®A home-based exercise intervention as well as standard care for your cancer as prescribed by your oncologist
Primary Outcome Measures
NameTimeMethod
Number of patients that adhered to the exercise conditions of the study3 Months

Measured by the Short Physical Performance Battery (SPPB) in patients with advanced GI malignancies

Secondary Outcome Measures
NameTimeMethod
Porportion of subjects with improved cachexia-related symptoms 3 months3 Months

The Functional Assessment of Anoreix/Cachexia Therapy subscale is a 39-item questionnaire that measures general aspects of quality of life as well as specific anorexia/cachexia-related concerns. This will be collected at pre- and post intervention

Trial Locations

Locations (1)

University of Rochester

🇺🇸

Rochester, New York, United States

© Copyright 2025. All Rights Reserved by MedPath